Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)
Completed · Phase 4 · NCT03419650
Conditions: Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $80,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- IRIS Research and Development, LLC (with Mallinckrodt)
- Tested
- ACTHar (drug)
- Dates
- Started 2018-07-20; completion 2021-08-25
- Results posted
- Not yet
Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.
From ClinicalTrials.gov, last updated 2021-08-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mallinckrodt Hospital Products Inc. reported $80,000 in research payments for this study in 2025 (1 payments).
Products named: Acthar
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Iris Research and Development LLC $80,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.